Jerry Durso was promoted to CEO last month, part of a broader shakeup in Intercept's leadership
February 23, 2021 07:16 AM ESTUpdated 07:55 AM
People

In­ter­cept shake­up con­tin­ues as CMO, for­mer NASH chief re­signs. Is the NASH biotech aban­don­ing its flag­ship dis­ease?

Jason Mast

Editor

First, they said good­bye to their found­ing CEO af­ter 18 years. Now, In­ter­cept is los­ing its CMO too, an ex­ec­u­tive who led the com­pa­ny’s flag­ship …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times